Hosted on MSN1mon
Tectonic jumps on positive data from early-stage trial for lead asset
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...
Hosted on MSN1mon
TECX Stock Hits 52-Week High, Soaring to $53.6 Amid Market Optimism
The TX45 treatment demonstrated significant improvements in left ventricular function and pulmonary hemodynamics, supporting the ongoing APEX Phase 2 clinical trial.